Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) — Market Cap & Net Worth
Market Cap & Net Worth: Acrivon Therapeutics, Inc. Common Stock (ACRV)
Acrivon Therapeutics, Inc. Common Stock (NASDAQ:ACRV) has a market capitalization of $52.70 Million ($52.70 Million) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21774 globally and #4864 in its home market, demonstrating a 23.53% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Acrivon Therapeutics, Inc. Common Stock's stock price $2.10 by its total outstanding shares 31555126 (31.56 Million). Also see balance sheet size of Acrivon Therapeutics, Inc. Common Stock for a full breakdown of the balance sheet.
Acrivon Therapeutics, Inc. Common Stock Market Cap History: 2022 to 2026
Acrivon Therapeutics, Inc. Common Stock's market capitalization history from 2022 to 2026. Data shows change from $363.52 Million to $66.27 Million (-41.48% CAGR). Also see Acrivon Therapeutics, Inc. Common Stock cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Acrivon Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.00% | #628 of 976 |
|
NASDAQ Composite
IXIC
|
$42.21 Trillion | 0.00% | #2075 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.87 Trillion | 0.00% | #247 of 263 |
Weight: Acrivon Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Acrivon Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Acrivon Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Acrivon Therapeutics, Inc. Common Stock for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACRV by Market Capitalization
Companies near Acrivon Therapeutics, Inc. Common Stock in the global market cap rankings as of September 26, 2026. Review how tangible is Acrivon Therapeutics, Inc. Common Stock's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Acrivon Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Acrivon Therapeutics, Inc. Common Stock Historical Marketcap From 2022 to 2026
Between 2022 and today, Acrivon Therapeutics, Inc. Common Stock's market cap moved from $363.52 Million to $ 66.27 Million, with a yearly change of -41.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $66.27 Million | -12.86% |
| 2025 | $76.05 Million | -59.97% |
| 2024 | $189.96 Million | +22.36% |
| 2023 | $155.25 Million | -57.29% |
| 2022 | $363.52 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Acrivon Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.70 Million USD |
| MoneyControl | $52.70 Million USD |
| MarketWatch | $52.70 Million USD |
| marketcap.company | $52.70 Million USD |
| Reuters | $52.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more